A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Trial Profile

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Entinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2017 Planned primary completion date changed from 31 Jul 2017 to 14 Jan 2021.
    • 07 Nov 2017 According to a Syndax Pharmaceuticals media release, this trial is 83% enrolled as of the end of October 2017. Completion of enrollment is expected in the first half of 2018. ECOG-ACRIN has completed the final progression free survival analysis and the first interim analysis for overall survival. The results of this analysis are held confidentially by the ECOG-ACRIN study statistician and the DSMC. The results of this analysis will be released upon completion of enrollment.
    • 10 Aug 2017 According to a Syndax Pharmaceuticals media release, as of the end of July, the trial was 78% enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top